XClose

UCL Division of Surgery and Interventional Science

Home
Menu

HALO-Radiofrequency-Ablation-Registry

Clinical trials: UK HALO Radiofrequency Ablation Registry

UCLH is the lead UK centre for this Registry, which maps outcomes for patients undergoing this novel therapy to treat Barrett’s oesophagus. There are currently 26 hospitals around the UK and in the Republic of Ireland who are contributing to the Registry.

What is the HALO RFA?

HALO Radiofrequency ablation (RFA) is a new treatment, which uses radio waves to destroy the dysplasia (abnormal changes). It can also be used to treat the entire area of Barrett’s oesophagus. The treatment is given during an endoscopy procedure and patients go home the same day.

How is the procedure performed?

Patients are given a sedative and a tiny probe is then used to deliver the radio waves to heat and rapidly remove the affected parts. The procedure takes about 45 minutes. This treatment is usually repeated three or four times at intervals of two to three months until not only the dysplasia, but also the entire Barrett’s Oesophagus has been removed.

What can I expect during or after the procedure?

The outcomes of this treatment for dysplasia look promising. Approximately 80-90% of patients have reversal of the dysplasia at the end of the course of treatment, which usually takes a few months to complete. It is still a new treatment and doctors need to establish how long the benefits last. For this reason, all patients having the treatment need to have follow-up endoscopies long-term to ensure they remain well. We have set up the UK HALO Registry to monitor outcomes and are currently inviting all patients to join this study.

The risk of developing oesophageal ‘heartburn cancer’ is high for people with Barrett’s oesophagus and high-grade dysplasia (badly formed pre-cancerous cells), at about 10 % per year, with half of all patients developing cancer in around five years. This means that half of these people will NOT develop cancer in five years. This needs to influence your decision about whether or not to have treatment.

People with low-grade dysplasia have a risk that is rather lower, at around 5% per year.

All people with dysplasia arising in Barrett’s oesophagus should be referred to a specialist centre where their case is discussed by a multi- disciplinary team of doctors. Patients may then be referred for this treatment. All the major UK centres are part of the UK Registry and patients should therefore be invited to enter their information anonymously into the Registry. There are no special requirements for entering this study.

The study is being run nationally by Professor Laurence Lovat and Dr Rehan Haidry. There are lead investigators at every participating hospital.

Hospitals currently enrolled include:

LONDON

University College London Hospital - Prof Lovat, Dr Haidry, Dr Banks, Dr Sweis

St Mary's Hospital, London - Dr Jonathan Hoare, Dr Natalie Direkze

Guy’s & St Thomas’ Hospital -  Dr Jason Dunn

ENGLAND

University Hospital Aintree - Dr Neil Kapoor

Royal Bournemouth and Christchurch Hospital - Dr Charles Gordon

Gloucestershire Royal Hospital - Prof Hugh Barr

Manchester Royal Infirmary - Dr Robert Willert

Queen Alexandra Hospital, Portsmouth - Dr Pradeep Bhandari

Royal Liverpool University Hospital - Dr Howard Smart, Dr Andrew Moore

Southampton University Hospital - Dr Praful Patel, Dr Phil Boger

Bradford Teaching Hospital - Dr Pradeep Mundre

Queen Elizabeth Hospital, Birmingham - Dr Brinder Mahon

Addenbrookes Hospital, Cambridge - Dr Fitzgerald, Massimiliano Di Pietro

Frimley Park Hospital - Dr Susannah Woodrow

Royal Wolverhampton Hospitals NHS - Dr Andrew Vietch

Norfolk & Norwich University Hospital - Mr Edward Cheong

Salford Royal NHS Foundation Trust - Dr Yeng Ang

Nottingham University Hospital NHS Trust - Prof Ragunath, Dr Ortiz Fernandez

County Durham & Darlington NHS Foundation Trust - Dr Anjan Dhar

Watford Hospital - Dr Anthony Leahy

Newcastle Hospitals - Dr David Nylander

John Radcliffe Hospital, Oxford - Dr Barbara Braden

Plymouth Hospital NHS Trust - Dr Sean Cochran

Broomfield Hospital, Chelmsford - Mr Venkatesh Jayanthi 

SCOTLAND

Glasgow Royal Infirmary - Dr Grant Fullarton, Jonathan Morris

Royal Infirmary, Edinburgh - Dr Ian Penman

IRELAND

St James, Dublin - Mr Ravi, Dermot O'Toole

UK HALO RFA Registry: http://www.barretts-oesophagus.co.uk/